|By Business Wire||
|June 11, 2014 04:05 PM EDT||
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will host an analyst day on June 19, 2014 at 12:30 p.m. EDT to discuss its next RNAi-based clinical candidate which targets a rare liver disease. A live webcast of the presentation and archive will be available on the Company’s website at www.arrowheadresearch.com. To access an audio only live presentation, dial 844-825-4406 toll free from the U.S. or 315-625-3230 for international callers and enter Conference ID 54600551.
During the event, a panel of disease area key opinion leaders will present information about the pathophysiology, patient populations, and current treatments for the disease. In addition, Arrowhead’s management will present nonclinical data and provide anticipated timelines for further development of the candidate.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary drug delivery technologies to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead technologies also enable partners to create peptide-drug conjugates that specifically home to cell types of interest while sparing off-target tissues. Arrowhead’s pipeline includes clinical programs in chronic hepatitis B virus and partner-based programs in obesity and oncology.
For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to [email protected].
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Arrowhead Research Corporation's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.
Cloud computing delivers on-demand resources that provide businesses with flexibility and cost-savings. The challenge in moving workloads to the cloud has been the cost and complexity of ensuring the initial and ongoing security and regulatory (PCI, HIPAA, FFIEC) compliance across private and public clouds. Manual security compliance is slow, prone to human error, and represents over 50% of the cost of managing cloud applications. Determining how to automate cloud security compliance is critical...
Nov. 29, 2015 10:00 PM EST Reads: 444
Nov. 29, 2015 06:00 PM EST Reads: 232
Nov. 29, 2015 06:00 PM EST Reads: 441
Nov. 29, 2015 04:00 PM EST Reads: 255
Nov. 29, 2015 02:00 PM EST Reads: 485
Nov. 29, 2015 01:00 PM EST Reads: 417
Nov. 29, 2015 01:00 PM EST Reads: 356
Nov. 29, 2015 12:45 PM EST Reads: 421
Nov. 29, 2015 12:30 PM EST Reads: 427
Nov. 29, 2015 12:00 PM EST Reads: 528
Nov. 29, 2015 11:45 AM EST Reads: 328
Nov. 29, 2015 11:30 AM EST Reads: 276
Nov. 29, 2015 10:00 AM EST Reads: 204
Nov. 29, 2015 09:45 AM EST Reads: 453
Nov. 29, 2015 09:15 AM EST Reads: 347